GEN-MKT-18-7897-A
Oct 13, 2020 | Biopharma, Blogs, Echo® MS+ system, Pharma | 0 comments
Imagine the productivity gains your lab could achieve with a technology that not only analyzes samples up to 50x faster than conventional quantitative LC-MS, but also eliminates tedious sample preparation, time-consuming LC method development and chromatographic run times.
Sound impossible? Not anymore.
Enter the new, exciting and very real Echo® MS System with:
Wait…no LC?
With its Acoustic Droplet Ejection (ADE) and Open Port Interface (OPI), the Echo MS System replaces conventional LC with game-changing technology that dramatically reduces the amount of time required for quantitative MS analysis. With no LC requirements, the Echo® MS System eliminates the need to spend time and effort developing separation methods. Troubleshooting LC problems and waiting for LC columns to wash, equilibrate and elute analytes disappear, all while delivering a speed of analysis that sets records for quantitative MS.
Imagine a 384 well plate finished in less than 7 minutes.1 With that kind of speed, entire discovery libraries containing millions of compounds can be quantitatively analyzed in a matter of days. Lead compounds are discovered faster, and project timelines can be radically accelerated.
Having this kind of speed means:
“Recently we heard comments from one of our collaborators. They are already starting to see the paradigm shift in their company. A lot of assays routinely run on the optical-based analytical instrument are now shifting to the mass-spec-based platform.”2Chang Liu, SCIEX R&D
With the Echo MS System, a fundamentally fast platform is combined with an effort-easing workflow that is more than the sum of its parts. With the capability to accelerate project turnaround times from months to weeks, days or even hours or minutes, the Echo MS System can dramatically improve your lab productivity.
To learn more about how you can massively scale up your productivity and RUN FAST, visit the Echo® MS System website for more information.
This blog is part 2 of a 3-part series on the Echo MS System. Read part 1 (How fast is fast? The Echo® MS System sets the record.), and part 3 (Scale it up! The Echo® MS System delivers unprecedented levels of productivity.).
References:
RUO-MKT-18-12283-A Echo® and Echo® MS are trademarks or registered trademarks of Labcyte Inc. in the United States and other countries, being used under license by SCIEX.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network